Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-Acquired complicated intra-Abdominal infections

Surgical Infections

Volumn 14, Issue 4, 2013, Pages 389-396

  Chen, Chao Wen ^a,b,c   Ming, Chu Chi ^d   Ma, Chien Jen ^a   Shan, Yen Shen ^e   Yeh, Yung Sung ^a   Wang, Jaw Yuan ^a,c,e  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; SULTAMICILLIN;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COMMUNICABLE DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SINGLE BLIND PROCEDURE;

ADULT; AGED; AGED, 80 AND OVER; AMPICILLIN; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES; RISK FACTORS; SULBACTAM; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84882936471     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2012.017     Document Type: Article

References (21)

1. Mazuski JE. Antimicrobial treatment for intra-Abdominal infections. Expert Opin Pharmacother 2007;8:2933-2945.
2. Nadler EP, Gaines BA. The Surgical Infection Society guidelines on antimicrobial therapy for children with appendicitis. Surg Infect (Larchmt) 2008;9:75-83.
3. Weigelt JA. Empiric treatment options in the management of complicated intra-Abdominal infections. Cleve Clin J Med 2007;74 (Suppl 4):S29-S37.
4. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intraabdominal infections. Clin Infect Dis 2003;37:997-1005.
5. Swenson BR, Metzger R, Hedrick TL, et al. Choosing antibiotics for intra-Abdominal infections: what do we mean by high risk? Surg Infect (Larchmt) 2009;10:29-39.
6. Guidelines for antimicrobial therapy of intra-Abdominal infections in adults. J Microbiol Immunol Infect 2008;41: 279-281.
7. Hasper D, Schefold JC, Baumgart DC. Management of severe abdominal infections. Recent Pat Antiinfect Drug Discov 2009;4:57-65.
8. Solomkin J, Zhao YP, Ma EL, et al. Moxifloxacin is noninferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-Abdominal infections. Int J Antimicrob Agents 2009; 34:439-445.
9. Malangoni MA, Song J, Herrington J, et al. Randomized controlled trial of moxifloxacin compared with piperacillintazobactam and amoxicillin-clavulanate for the treatment of complicated intra-Abdominal infections. Ann Surg 2006;244: 204-211.
10. Weiss G, Reimnitz P, Hampel B, et al. Moxifloxacin for the treatment of patients with complicated intra-Abdominal infections (the AIDA Study). J Chemother 2009;21:170-180.
11. Lin H-L, Kuo L-C, Chen C-W, et al. Reply to letter entitled Timing and mode of surgery for inflammatory omental cyst questioned. J Formosan Med Assoc 2009;108:974-975.
12. Schnuriger B, Inaba K, Eberle BM, et al. Microbiological profile and antimicrobial susceptibility in surgical site infections following hollow viscus injury. J Gastrointest Surg 2010;14:1304-1310.
13. Betrosian AP, Douzinas EE. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections. Expert Opin Drug Metab Toxicol 2009;5:1099-1112.
14. Lode HM. Rational antibiotic therapy and the position of ampicillin-sulbactam. Int J Antimicrob Agents 2008;32:10-28.
15. Bodmann KF. [Complicated intra-Abdominal infections: pathogens, resistance. Recommendations of the Infectliga on antibiotic therapy]. Chirurg 2010;81:38-49.
16. Mazuski JE, Solomkin JS. Intra-Abdominal infections. Surg Clin North Am 2009;89:421-437, ix.
17. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-Abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010;11:79-109.
18. Falagas ME, Barefoot L, Griffith J, et al. Risk factors leading to clinical failure in the treatment of intra-Abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996;15:913-921.
19. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-2751.
20. Siddiqui S, Salahuddin N, Raza A, Razzak J. How early do antibiotics have to be to impact mortality in severe sepsis? A prospective, observational study from an emergency department. J Ayub Med Coll Abbottabad 2009;21:106-110.
21. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010;38: 1045-1053.